Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer

Next Previous
Trial Profile

A Phase 1/2 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Balstilimab (Primary) ; Botensilimab (Primary)
  • Indications Cervical cancer; Colorectal cancer; Endometrial cancer; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Agenus

Most Recent Events

  • 15 May 2025 According to an Agenus media release, the company announced that new data from this study will be presented at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Barcelona, Spain. A poster presentation will feature updated findings from an expanded cohort of 123 patients, incorporating additional participants and extended follow-up to further assess clinical activity of the combination, including durability of response and overall survival.
  • 12 May 2025 According to an Agenus media release, Data on late stage pan tumor activity to be presented at an upcoming key cancer conference.
  • 12 May 2025 According to an Agenus media release, new data from the HCC cohort were presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top